Recombinant DNA-derived coagulation factor VIII concentrate (recombinant) price details and purchase methods

Recombinant DNA-derived coagulation factor VIII concentrate (Altuiiio) is an innovative drug approved by the FDA for the treatment of adults and children with hemophilia type A (congenital factor VIII deficiency). Altuiiiio enables routine prophylaxis to reduce the frequency of bleeding episodes, as well as on-demand treatment and control of bleeding events, as well as perioperative bleeding management. However, it should be noted that Altuiiiio is not suitable for treating von Willebrand's disease.

As a recombinant or synthetic factor VIII (FVIII) replacement therapy, Altuiiiio uses technology that does not rely on von Willebrand Factor (VWF). This gives Altuiiio a unique advantage in terms of therapeutic effect. Because it does not rely on VWF, the drug's half-life is 3 to 4 times longer than other standard and extended half-life FVIII products, meaning the drug's effect lasts significantly longer. This allows patients to maintain effective treatment effects with just one injection per week, thereby improving treatment convenience and patient compliance.

Altuiiiio is designed to provide hemophilia patients with a more efficient and flexible treatment option. By reducing the frequency of bleeding events, patients can enjoy a greater sense of security and confidence in their daily lives and be able to perform various medical procedures more smoothly. Its application in the perioperative period enables medical teams to effectively manage bleeding risks and provide patients with more comprehensive care.

To sum up,Altuiiio, as a recombinant coagulation factor VIII replacement therapy, has demonstrated good efficacy and safety in clinical application. Its unique drug properties make it an important choice for patients with hemophilia A, providing new possibilities for improving their quality of life. The development of this drug not only promotes progress in the field of hemophilia treatment, but also brings hope and good news to patients.

In China, there are currently no therapeutic preparations such as recombinantDNA-derived coagulation factor VII concentrate. If patients need to use this drug, they should consult a regular overseas medical consultant for accurate information.

Reference link: https://www.drugs.com/altuviiio.html